We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

By LabMedica International staff writers
Posted on 23 May 2024

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. More...

These conditions are caused by the clumping together of the smallest building blocks in the body that disrupts vital functions. Within our cells, numerous interactions and exchanges among proteins and other molecules occur naturally, allowing our bodies to function properly. However, errors in these processes can lead to protein clumps that impair functionality, underpinning a variety of neurodegenerative disorders affecting the brain, including Alzheimer's and dementia. Understanding why this clumping occurs and how to treat it has remained elusive, largely due to a lack of adequate tools to study these phenomena. Researchers have now introduced a groundbreaking tool that can find these tiny protein clumps in microscopy images and lead to improved understanding and treatments of diseases like cancer, Alzheimer's, and Parkinson's.

Scientists at the University of Copenhagen (Copenhagen, Denmark) have developed a machine learning algorithm capable of observing protein clumping in real time under a microscope. This algorithm is capable of automatically identifying and monitoring the critical characteristics of the clumped-up building blocks responsible for Alzheimer's and other neurodegenerative diseases—a task previously unachievable. It can detect protein clumps as small as a billionth of a meter in microscopy images and categorize these clumps by their shape and size while tracking their development. The physical appearance of these clumps significantly influences their function and behavior within the body, whether detrimental or beneficial.

Going forward, this algorithm will simplify the process of discovering why clumps form, thereby aiding the development of new medications and therapies to fight these debilitating disorders. The researchers are actively using this tool in experiments with insulin molecules, which, when clumped, lose their ability to regulate blood sugar effectively. The tool allows for the observation of how these clumps change when exposed to various compounds, paving the way to potentially halt or alter them into less harmful or more stable forms. The team is optimistic about the tool's potential to facilitate drug development once these tiny building blocks are precisely identified. They anticipate that their efforts will initiate the gathering of more comprehensive knowledge regarding the shapes and functions of proteins and molecules. The algorithm is accessible as open-source software on the internet for use by scientific researchers and others interested in exploring the clumping of proteins and other molecules.

"In just minutes, our algorithm solves a challenge that would take researchers several weeks. That it will now be easier to study microscopic images of clumping proteins will hopefully contribute to our knowledge, and in the long term, lead to new therapies for neurodegenerative brain disorders," said PhD Jacob Kæstel-Hansen, who led the research team behind the algorithm.

Related Links:
University of Copenhagen


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.